Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 1/20 | 0.37 |
| ▸ | ADH1A | P07327 | 1/20 | 0.37 |
| ▸ | ADH7 | P40394 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25086388 | 0.74 | ADH1B (0.39) | ADH1BADH1AADH7 | |
| SCHEMBL22702044 | 0.73 | — | — | |
| SCHEMBL25918901 | 0.71 | — | — | |
| SCHEMBL22702025 | 0.71 | CARM1 (0.42) | — | |
| SCHEMBL22892887 | 0.70 | — | — | |
| SCHEMBL22103778 | 0.70 | ADH1B (0.39) | ADH1BADH1AADH7 | |
| SCHEMBL25801503 | 0.70 | ADH1B (0.34) | ADH1BADH1AADH7 | |
| SCHEMBL21985272 | 0.70 | ALDH1A1 (0.44) | — | |
| SCHEMBL21085365 | 0.68 | — | — | |
| SCHEMBL12281011 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-10166250-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN MA INC. (US) | 2019-01-01 | — | — | US | disclosed |
| US-20180133233-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN MA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133233-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | S1PR1, S1PR3, S1PR4 | ADH1B 4691/4885ADH1A 2498/4885ADH7 4504/4885 |
| US-10166250-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | S1PR1, S1PR3, S1PR4 | ADH1B 4691/4885ADH1A 2498/4885ADH7 4504/4885 |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | ADH1B 3071/4885ADH1A 4265/4885ADH7 3009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.